Roivant Neurosciences Ltd., a biopharmaceutical company focused on the development and commercialization of late-stage drug candidates for neurologic diseases, has entered into an agreement with GlaxoSmithKline (GSK) for the acquisition of SB742457, a selective 5-HT6 receptor antagonist that is being developed as an oral treatment for subjects with mild-to-moderate Alzheimer’s disease.

GSK conducted 13 clinical studies of SB742457 involving over 1,250 healthy subjects and Alzheimer’s disease patients. The results of these studies provide evidence that SB742457 holds promise for patients with mild-to-moderate Alzheimer’s disease. Roivant intends to meet with the US Food and Drug Administration in the first half of 2015 to confirm the regulatory requirements for the continued development of SB742457 for the treatment of the signs and symptoms of mild-to-moderate Alzheimer’s disease. Roivant may also explore the clinical development of SB742457 for other neurological disorders for which there are limited or no therapeutic options.

Roivant Neurosciences Ltd. is a wholly owned subsidiary of Roivant Sciences Ltd., a biopharmaceutical firm focused on the late-stage clinical development and commercialization of nonstrategic, deprioritized or under-resourced drug candidates. Backed by a global multi-strategy investment firm and an international specialty pharmaceutical company, Roivant Sciences uses its capital and in-house drug development expertise to move programs forward across a variety of pharmaceutical indications.

Source: Roivant